Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Ribomic USA Inc
- Target Recruit Count
- 40
- Registration Number
- NCT04640272
- Locations
- 🇺🇸
Retinal Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸Retinal Medical Consultants Group, Sacramento, California, United States
🇺🇸Bay Area Retina Associates, Walnut Creek, California, United States
A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration
- Conditions
- Exudative Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Ribomic USA Inc
- Target Recruit Count
- 94
- Registration Number
- NCT04200248
- Locations
- 🇺🇸
Retinal Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸Retinal Consultants Medical Group, Sacramento, California, United States
🇺🇸Bay Area Retina Associates, Walnut Creek, California, United States
RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration
- Conditions
- Age-related Macular Degeneration
- Interventions
- Drug: RBM-007 Injectable Solution
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Ribomic USA Inc
- Target Recruit Count
- 9
- Registration Number
- NCT03633084
- Locations
- 🇺🇸
Retinal Consultants Medical Group, Sacramento, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Bay Area Retina Associates, Walnut Creek, California, United States